|
Association of the clinical cell-cycle risk score with metastasis after radiation therapy and identification of men with prostate cancer who can forgo combined androgen deprivation therapy. |
|
|
Consulting or Advisory Role - Bayer; Blue Earth Diagnostics; Janssen Scientific Affairs; Merck; Myriad Genetics |
Research Funding - Bayer (Inst) |
Expert Testimony - Expert Consulting Services |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Dendreon; Ferring; Genentech/Roche; Janssen Scientific Affairs; Medivation/Astellas; Merck; Myovant Sciences; Pfizer; Tolmar |
Speakers' Bureau - Bayer; Dendreon; Janssen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Astellas Pharma; Dendreon; miR Scientific; Urotronic |
Stock and Other Ownership Interests - Egenix; Exelixis (I) |
Research Funding - Advantagene (Inst); Dendreon (Inst); Medivation (Inst) |
Travel, Accommodations, Expenses - Integrated Medical Professionals |
Other Relationship - American Urological Association |
|
|
No Relationships to Disclose |
|
|
Research Funding - Janssen Oncology (Inst) |
|
|
|
Consulting or Advisory Role - Ambu; Myriad Genetics |
Speakers' Bureau - Janssen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; MDxHealth; Pfizer |
Speakers' Bureau - Astellas Amgen BioPharama; MDxHealth; Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Myriad Genetics |
Stock and Other Ownership Interests - Myriad Genetics |
|
|
Employment - Myriad Genetics |
Stock and Other Ownership Interests - Myriad Genetics |
|
|
Employment - Myriad Genetics |
Stock and Other Ownership Interests - Myriad Genetics |